MarkWBurketMD
Cardiology • Toledo, OHAdult Congenital Heart Disease, Cardiac Electrophysiology, Interventional Cardiology
Professor, Medicine, University of Toledo College of Medicine
Dr. Burket is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3000 Arlington Ave.
Toledo, OH 43614Phone+1 419-383-6095
Education & Training
University of ToledoFellowship, Cardiovascular Disease, 1982 - 1985
Ohio State University HospitalResidency, Internal Medicine, 1979 - 1982- Ohio State University College of MedicineClass of 1979
Certifications & Licensure
OH State Medical License 1981 - 2025
MI State Medical License 1986 - 2008- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
- American Board of Internal Medicine Interventional Cardiology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2014
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Fellow (FACC) American College of Cardiology
Clinical Trials
- Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents Start of enrollment: 2011 Jul 01
- Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension Start of enrollment: 2012 Oct 23
- Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis Start of enrollment: 2014 Mar 01
Publications & Presentations
PubMed
- 399 citationsEffect of transradial access on quality of life and cost of cardiac catheterization: A randomized comparison.Christopher J. Cooper, Reda A. El-Shiekh, David J. Cohen, Linda Blaesing, Mark W. Burket
American Heart Journal. 1999-09-01 - 431 citationsPaclitaxel-Eluting Stents Show Superiority to Balloon Angioplasty and Bare Metal Stents in Femoropopliteal Disease Twelve-Month Zilver PTX Randomized Study ResultsMichael D. Dake, Gary M. Ansel, Michael R. Jaff, Takao Ohki, Richard R. Saxon
Circulation. Cardiovascular Interventions. 2011-09-27 - 153 citationsA polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL...William A. Gray, Koen Keirse, Yoshimitsu Soga, Andrew Benko, Anvar Babaev
Lancet. 2018-10-27
Press Mentions
What Should Emerging Cardiology Leaders Know? 5 Industry Leaders Weigh InSeptember 14th, 2021
Two-Year-Data Presented from BIOLUX P-III Registry of Biotronik's Passeo-18 Lux DCBApril 18th, 2019
BIOTRONIK’s Pulsar-18 Stent with Thin Delivery System for Superficial Femoral Arteries Now AvailableJuly 5th, 2017
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
